Emily Lebow, MD

Radiation onc @PennMedicine | Brain tumor research | Mom 👧🏻👧🏻 | Alum of @MSK_RadOnc @Harvardmed @Penn

[Emily Lebow, MD @EmilyLebow]

@PDBrownOnc Amazing! What do you think of the OS difference?

[Steven Brem @StevenBremMD]

🧵1/3 Kudos to Cole Friedes, Melanie Berger, Lauren Linkowski, @EmilyLebow and colleagues in the Penn Brain Tumor Center for their publication today on clinical, molecular and immunologic determinants of #survival in #WHO-defined #IDH-wt #glioblastoma treated with #radiotherapy - a large real-world cohort study.
@PennRadOnc @PennNSG @PennCancer @PennMedCSO

https://t.co/7UESd3JZqf

[Emily Lebow, MD @EmilyLebow]

@PennMedCSO @JNikitasMD @PennRadOnc @RO_Institute Congratulations!

[Henning Willers, MD, FASTRO @HenningWillers]

Always a highlight of @ASTRO_org Meetings, the Awards ceremony🔥 Because we like to celebrate our community🥳

Huge shoutout to classmate, friend, role model, and mentoring force Helen Shih of MGH/MGB👏👏👏 (now she just needs to join #SoMe‼️)

#ASTRO25

@DKirschMDPhD @AmyWisdom8 @EmilyLebow

[Emily Lebow, MD @EmilyLebow]

Special thanks to @JHGLab, @LiaHalaszMD , @KylieKangMD, Luke Pike. @RachelJimenezMD, @DrWilliamHwang, @BrandonMahal, @MinaBakhtiar, @AmyWisdom8, @ShervinTabrizi, @theabzlab, @EJVaios, @DanielKimMD, and many others who contributed to the nomination 🙌 @HarvardRadOnc

[Emily Lebow, MD @EmilyLebow]

I was privileged to nominate Dr Helen Shih for the ASTRO Mentorship Award and thrilled to see her honored this year along side Drs Gibbs and Yahalom🌟 She’s been an incredible mentor to me since med school in 2016, shaping my path in rad onc and inspiring me to mentor others

[ASTRO @ASTRO_org]

Congratulations to Iris Gibbs, MD, FASTRO; Helen Shih, MD, MS, MPH, FASTRO; & Joachim Yahalom, MD, FASTRO on their 2025 ASTRO Mentorship awards!!
They will be recognized at #ASTRO25 in San Francisco. @StanfordRadOnc @MassGeneralNews @MSK_RadOnc
https://t.co/TIGyGv8Zfq

[Penn Medicine @PennMedicine]

#ASCO25: @StephenBagleyMD on CAR T cell for glioblastoma: “The treatment changed the trajectory of their disease.” Now in @NatureMedicine and on the @ASCO stage today. Abstract 102. @DrORourke2 https://t.co/1qzmYYZN66

[Emily Lebow, MD @EmilyLebow]

@UCSDCancer @KathrynTringale @NCCN Congratulations @KathrynTringale!

[UC San Diego Health Moores Cancer Center @UCSDCancer]

The @NCCN Foundation has announced MCC member, Kathryn Tringale, MD, MAS, as a 2025 Young Investigator Award recipient.

This award recognizes her impact on cancer care through neuroimaging and biomarker research on neurotoxicity after CAR T-cell therapy: https://t.co/5b5zyPjgXH.

[Michelle Monje 🟦 @michelle_monje]

#CARTcells for #DIPG #DMG clinical trial (1st arm) results are out today. Full Tweetorial coming, but first want to share the story of a patient whose #DIPG has disappeared for over 3 years. It is a milestone and moment of hope on a journey filled with so much grief.
“There’s a lot of loss that led to this research,” Drew’s dad said. “I hope those families know that this success is because of them.”
https://t.co/rNnHkL6pQR

[Emily Lebow, MD @EmilyLebow]

Thanks, @HenningWillers! Great to present promising options for pts with locally advanced #lungcancer who are ineligible for chemoRT. @MSKCancerCenter @MSK_RadOnc

[Henning Willers, MD, FASTRO @HenningWillers]

1/2
Promising outcomes of combining #radiotherapy and durvalumab without chemo in LA-NSCLC.
PFS associated with PD-L1.

Wonder if there is a path for personalized therapy where chemo can be dropped in high PDL1?

#ASTRO24

[Emily Lebow, MD @EmilyLebow]

@NehaVapiwala Congratulations!!

[Emily Lebow, MD @EmilyLebow]

@Ali_Nabavizadeh @jana_ivanidze @PennMedicine @PennRadiology Congratulations!

[Memorial Sloan Kettering Radiation Oncology @MSK_RadOnc]

🧠☢️⚡️New in @JAMAOnc from @MSKCancerCenter #radonc grad Dr @EmilyLebow w/ Dr @yaoyu_md: Antibody-drug conjugates given concurrently with Stereotactic #radiotherapy #SRS were associated with ⬆️risk of symptomatic #radiation necrosis.
More details here: https://t.co/F2Q0i1Zoog

[Memorial Sloan Kettering Radiation Oncology @MSK_RadOnc]

🫁☢️New in @jitcancer from @MSKCancerCenter #radonc and @DanaFarber: This analysis of outcomes to #chemoradiation & #durvalumab in stage III non-small cell #lungcancer #NSCLC suggests that tumor aneuploidy is a promising predictive biomarker. #lcsm
➡️https://t.co/GrrTZCp9OU

[Brain Metastasis Program @ MSK @BrainMets_MSK]

Just out in @JAMAOnc - important data on risk factors for #brainmet necrosis with concurrent ADC + SRS: understanding sequencing essential as CNS outcome data emerge @MSK_RadOnc @MSK_DeptOfMed @MSKNeurosurgery @EmilyLebow @yaoyu_md @Dr_Luke_Pike @Dr_N_Moss

[Yao Yu @yaoyu_md]

Happy to share our work on SRS with concurrent ADCs, now out @JAMAOnc! In this study, led by @EmilyLebow, we investigated the risk of symptomatic radiation necrosis for pts receiving SRS and brain metastases. ADCs included T-DXd, T-DM1, and SG. (1/n)
https://t.co/dplp1nJKmW

[JAMA Oncology @JAMAOnc]

In this study, giving an antibody-drug conjugates (T-DXd, T-DM1, SG) concurrently with stereotactic radiotherapy was associated w/ higher risk of radiation necrosis. The absolute risk was low for small lesions, but increased rapidly w/ volume & prior RT. https://t.co/XaRdIu5e3x

[Emily Lebow, MD @EmilyLebow]

In @FrontiersIn we highlight the potential of #ctDNA to guide personalized therapy for patients with #lungcancer

Thank you @NateraOncology, @Natera, @YoninaMG , Bob Li, @danielrgomez44, Andreas Rimner & many more at @MSK_RadOnc @MSKCancerCenter!

🔗 https://t.co/npLr08ugOU